Lamotrigine vs levetiracetam in female patients of childbearing age with juvenile absence epilepsy: A Bayesian reanalysis.
anti‐seizure medication (ASM)
first‐line
idiopathic generalized epilepsy (IGE)
monotherapy
women
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
10 Aug 2024
10 Aug 2024
Historique:
revised:
02
07
2024
received:
21
05
2024
accepted:
25
07
2024
medline:
10
8
2024
pubmed:
10
8
2024
entrez:
10
8
2024
Statut:
aheadofprint
Résumé
Women of childbearing age with juvenile absence epilepsy (JAE) face treatment challenges due to limited access to safe and effective anti-seizure medications (ASMs). In a previous study we compared the effectiveness of levetiracetam (LEV) and lamotrigine (LTG) in women with idiopathic generalized epilepsy (IGE), highlighting a superiority of LEV in juvenile myoclonic epilepsy. In this study, we specifically reanalyzed, through a Bayesian approach and by expanding the previously published cohort, the comparative effectiveness of these ASMs as initial monotherapy in JAE. We conducted a multicenter, retrospective, comparative effectiveness study on women of childbearing age diagnosed with JAE and prescribed LEV or LTG as the initial ASM. Inverse probability treatment weighting (IPTW) Bayesian Cox proportional hazard models were employed to evaluate treatment failure (TF) due to ineffectiveness and ASM retention. The patients' center of provenance and year of prescription were considered as random effect factors. Posterior probabilities and relative log-risk distribution were computed, and the distribution of posterior draws was analyzed to assess the evidence supporting LTG superiority over LEV. Of 123 patients, those treated with LTG (n = 67) demonstrated lower TF and higher ASM retention than those treated with LEV (n = 56), with the IPTW-weighted Bayesian Cox proportional hazards model showing a 99.2% posterior probability of LTG being superior on TF and a 99.5% probability on ASM retention. Additional analyses on ≥50% and ≥75% seizure reduction through IPTW-weighted Bayesian logistic regression largely confirmed these findings, whereas the two ASMs did not show evident differences in terms of seizure freedom. The two ASMs showed comparable safety profiles, with only a minority of patients discontinuing treatment due to side effects. Bayesian reanalysis supports LTG as first-line monotherapy for JAE in women of childbearing age, emphasizing the importance of individualized treatment strategies in women with IGE. This study underscores the value of Bayesian methods in refining clinical research and treatment decisions.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 International League Against Epilepsy.
Références
Chu H, Zhang X, Shi J, Zhou Z, Yang X. Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta‐analysis. J Neurol. 2023;270(10):4713–4728. https://doi.org/10.1007/s00415‐023‐11834‐8
Battino D, Tomson T, Bonizzoni E, Craig J, Perucca E, Sabers A, et al. Risk of major congenital malformations and exposure to antiseizure medication monotherapy. JAMA Neurol. 2024;81:481–489. https://doi.org/10.1001/jamaneurol.2024.0258
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, et al. The SANAD II study of the effectiveness and cost‐effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open‐label, non‐inferiority, multicentre, phase 4, randomised controlled trial [published correction appears in Lancet. 2021 Apr 24;397(10284):1544] [published correction appears in Lancet. 2021 May 15;397(10287):1808]. Lancet. 2021;397(10282):1375–1386. https://doi.org/10.1016/S0140‐6736(21)00246‐4
Cerulli Irelli E, Cocchi E, Morano A, Gesche J, Caraballo RH, Lattanzi S, et al. Predictors of seizure recurrence in women with idiopathic generalized epilepsy who switch from valproate to another medication. Neurology. 2024;102(9):e209222. https://doi.org/10.1212/WNL.0000000000209222
Mbizvo GK, Bucci T, Lip GYH, Marson AG. Morbidity and mortality risks associated with valproate withdrawal in young men and women with epilepsy. Brain. 2024;awae128. https://doi.org/10.1093/brain/awae128. online ahead of print.
Cohen JM, Alvestad S, Suarez EA, Schaffer A, Selmer RM, Havard A, et al. Comparative risk of major congenital malformations with antiseizure medication combinations vs valproate monotherapy in pregnancy. Neurology. 2024;102(2):e207996. https://doi.org/10.1212/WNL.0000000000207996
Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696–1703. https://doi.org/10.1001/jama.2013.2270
Cerulli Irelli E, Cocchi E, Mostacci B, Orlando B, Gesche J, Caraballo RH, et al. Topiramate ban in women of childbearing potential with idiopathic generalized epilepsy: does effectiveness offset the teratogenic risks? Epilepsia. 2024;65(3):e27–e34. https://doi.org/10.1111/epi.17892
Cerulli Irelli E, Cocchi E, Morano A, Gesche J, Caraballo RH, Lattanzi S, et al. Levetiracetam vs lamotrigine as first‐line antiseizure medication in female patients with idiopathic generalized epilepsy. JAMA Neurol. 2023;80(11):1174–1181. https://doi.org/10.1001/jamaneurol.2023.3400
Mostacci B, Ranzato F, Giuliano L, la Neve A, Aguglia U, Bilo L, et al. Alternatives to valproate in girls and women of childbearing potential with idiopathic generalized epilepsies: state of the art and guidance for the clinician proposed by the epilepsy and gender Commission of the Italian League against Epilepsy (LICE). Seizure. 2021;85:26–38. https://doi.org/10.1016/j.seizure.2020.12.005
Glauser T, Ben‐Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563. https://doi.org/10.1111/epi.12074
National Institute for Health and Care Excellence [NICE]. Epilepsies in children, young people and adults (NG217). 2022. Available from: https://www.nice.org.uk/guidance/ng217/resources/epilepsies‐in‐children‐young‐people‐and‐adults‐pdf‐66143780239813. Accessed 21 Apr 2024.
Bolstad WM, Curran JM. Introduction to Bayesian statistics. Hoboken: John Wiley & Sons; 2016.
Winkler RL. Why Bayesian analysis hasn't caught on in healthcare decision making. Int J Technol Assess Health Care. 2001;17(1):56–66. https://doi.org/10.1017/s026646230110406x
Yarnell CJ, Abrams D, Baldwin MR, Brodie D, Fan E, Ferguson ND, et al. Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making? Lancet Respir Med. 2021;9(2):207–216. https://doi.org/10.1016/S2213‐2600(20)30471‐9
Angriman F, Muttalib F, Lamontagne F, Adhikari NKJ, LOVIT Investigators. IV vitamin C in adults with sepsis: a Bayesian reanalysis of a randomized controlled trial. Crit Care Med. 2023;51(8):e152–e156. https://doi.org/10.1097/CCM.0000000000005871
Harhay MO, Blette BS, Granholm A, Moler FW, Zampieri FG, Goligher EC, et al. A Bayesian interpretation of a pediatric cardiac arrest trial (THAPCA‐OH). NEJM Evid. 2023;2(1):EVIDoa2200196. https://doi.org/10.1056/EVIDoa2200196
Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Jüni P, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial [published correction appears in JAMA. 2019 Jun 11;321(22):2245]. JAMA. 2018;320(21):2251–2259. https://doi.org/10.1001/jama.2018.14276
Lammers D, Richman J, Holcomb JB, Jansen JO. Use of Bayesian statistics to reanalyze data from the pragmatic randomized optimal platelet and plasma ratios trial. JAMA Netw Open. 2023;6(2):e230421. https://doi.org/10.1001/jamanetworkopen.2023.0421
Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report–Part I. Value Health. 2009;12(8):1044–1052. https://doi.org/10.1111/j.1524‐4733.2009.00600.x
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. https://doi.org/10.1016/S0140‐6736(07)61602‐X
Hirsch E, French J, Scheffer IE, Bogacz A, Alsaadi T, Sperling MR, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1475–1499. https://doi.org/10.1111/epi.17236
Moons KG, Donders RA, Stijnen T, Harrell FE Jr. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol. 2006;59(10):1092–1101. https://doi.org/10.1016/j.jclinepi.2006.01.009
Cerulli Irelli E, Morano A, Cocchi E, Casciato S, Fanella M, Albini M, et al. Doing without valproate in women of childbearing potential with idiopathic generalized epilepsy: implications on seizure outcome. Epilepsia. 2020;61(1):107–114. https://doi.org/10.1111/epi.16407
Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry. 2004;75(1):75–79.
Cerulli Irelli E, Morano A, Orlando B, Salamone EM, Fanella M, Fattouch J, et al. Seizure outcome trajectories in a well‐defined cohort of newly diagnosed juvenile myoclonic epilepsy patients. Acta Neurol Scand. 2022;145(3):314–321. https://doi.org/10.1111/ane.13556
Hainsworth AH, McNaughton NC, Pereverzev A, Schneider T, Randall AD. Actions of sipatrigine, 202W92 and lamotrigine on R‐type and T‐type Ca2+ channel currents. Eur J Pharmacol. 2003;467(1–3):77–80. https://doi.org/10.1016/s0014‐2999(03)01625‐x
Surges R, Volynski KE, Walker MC. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited [published correction appears in Ther Adv Neurol Disord. 2008 Sep;1(2):79]. Ther Adv Neurol Disord. 2008;1(1):13–24. https://doi.org/10.1177/1756285608094212
Ernst WL, Zhang Y, Yoo JW, Ernst SJ, Noebels JL. Genetic enhancement of thalamocortical network activity by elevating alpha 1g‐mediated low‐voltage‐activated calcium current induces pure absence epilepsy. J Neurosci. 2009;29(6):1615–1625. https://doi.org/10.1523/JNEUROSCI.2081‐08.2009
Nolan D, Lester SG, Rau SM, Shellhaas RA. Clinical use and efficacy of levetiracetam for absence epilepsies. J Child Neurol. 2019;34(2):94–98. https://doi.org/10.1177/0883073818811511
Auvin S, Chhun S, Berquin P, Ponchel E, Delanoë C, Chiron C. Aggravation of absence seizure related to levetiracetam. Eur J Paediatr Neurol. 2011;15(6):508–511. https://doi.org/10.1016/j.ejpn.2011.05.007
Gesche J, Hjalgrim H, Rubboli G, Beier CP. Patterns and prognostic markers for treatment response in generalized epilepsies. Neurology. 2020;95(18):e2519–e2528. https://doi.org/10.1212/WNL.0000000000010644
Fattore C, Boniver C, Capovilla G, Cerminara C, Citterio A, Coppola G, et al. A multicenter, randomized, placebo‐controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia. 2011;52(4):802–809. https://doi.org/10.1111/j.1528‐1167.2010.02976.x
Frank LM, Enlow T, Holmes GL, Manasco P, Concannon S, Chen C, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia. 1999;40(7):973–979. https://doi.org/10.1111/j.1528‐1157.1999.tb00805.x
Holmes GL, Frank LM, Sheth RD, Philbrook B, Wooten JD, Vuong A, et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res. 2008;82(2–3):124–132. https://doi.org/10.1016/j.eplepsyres.2008.07.016
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362(9):790–799. https://doi.org/10.1056/NEJMoa0902014
Isojärvi JI, Taubøll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs. 2005;19(3):207–223. https://doi.org/10.2165/00023210‐200519030‐00003
Chen B, Choi H, Hirsch LJ, Moeller J, Javed A, Kato K, et al. Cosmetic side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2015;42:129–137. https://doi.org/10.1016/j.yebeh.2014.10.021
Nucera B, Brigo F, Trinka E, Kalss G. Treatment and care of women with epilepsy before, during, and after pregnancy: a practical guide. Ther Adv Neurol Disord. 2022;15:17562864221101687. https://doi.org/10.1177/17562864221101687
Veroniki AA, Cogo E, Rios P, Straus SE, Finkelstein Y, Kealey R, et al. Comparative safety of anti‐epileptic drugs during pregnancy: a systematic review and network meta‐analysis of congenital malformations and prenatal outcomes. BMC Med. 2017;15(1):95. https://doi.org/10.1186/s12916‐017‐0845‐1
Asadi‐Pooya AA, Farazdaghi M. Childhood vs. juvenile absence epilepsy: how to make a diagnosis. Seizure. 2022;102:125–128. https://doi.org/10.1016/j.seizure.2022.10.008
Glauser TA, Morita DM. Ethosuximide. In: Wylie E, Gupta A, Lachhwani DK, editors. The treatment of epilepsy: principles and practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
Glauser T, Ben‐Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence‐based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094–1120. https://doi.org/10.1111/j.1528‐1167.2006.00585.x
Yin X, Liu Y, Guo Y, Zhao L, Li G, Tan X. Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy. CNS Neurosci Ther. 2022;28(5):658–666. https://doi.org/10.1111/cns.13796
Rauchenzauner M, Deichmann S, Pittschieler S, Bergmann M, Prieschl M, Unterberger I, et al. Bidirectional interaction between oral contraception and lamotrigine in women with epilepsy—role of progestins. Seizure. 2020;74:89–92. https://doi.org/10.1016/j.seizure.2019.11.01
Pizarro J, O'Sullivan S, Walker MC. How accurately do adult patients report their absence seizures? Epilepsia Open. 2023;8(2):641–644. https://doi.org/10.1002/epi4.12689
Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co‐administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol. 2006;61(2):191–199. https://doi.org/10.1111/j.1365‐2125.2005.02539.x